As previously reported, Morgan Stanley upgraded Tandem Diabetes (TNDM) to Overweight from Equal Weight with an unchanged price target of $45. The stock has been under substantial pressure, down around 40% in the last 6 months, despite what the firm considers to be better than expected results and a successful MOBI rollout, says the analyst, who also thinks the stock is “looking too cheap now.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes upgraded to Overweight from Equal Weight at Morgan Stanley
- Tandem Diabetes price target raised to $60 from $58 at Barclays
- Tandem Diabetes price target lowered to $40 from $43 at UBS
- Tandem Diabetes price target lowered to $56 from $57 at Canaccord
- Tandem Diabetes price target lowered to $37 from $39 at Baird